Solving The Inhalation Puzzle: A CDMO's Guide To Dry Powder Development

Pulmonary and nasal routes have proven effective for delivering a range of therapeutics, including small molecules with limited solubility, compounds with systemic side effects, and novel biologics. Dry powders for inhalation (DPIs) are a particularly adaptable platform, offering enhanced stability compared to their liquid counterparts. However, the development strategy for DPIs hinges on crucial factors such as the required dosage, active pharmaceutical ingredient (API) physicochemical properties, and desired release profiles.

For instance, micronization via milling, often followed by blending with lactose, is well-suited for low-dose, stable crystalline small molecules. Conversely, spray drying technology can significantly improve the bioavailability of poorly soluble molecules and enable the micronization of biologics.

The increasing interest in pulmonary and nasal drug delivery has attracted many new players to the field. This webinar will provide a CDMO's perspective on the essential considerations for developing inhalation and nasal dry powder products.

Speakers offer guidance on formulation selection, excipients, and the micronization technologies available through CDMOs. The discussion also covers current encapsulation technologies for inhaled products. This information aims to empower innovators to make informed decisions for successful inhalation product development.

Key Learning Objectives:

• Understand how the Target Product Profile (TPP) influences the development pathway for inhaled drug products.
• Gain insights into formulation options and particle engineering technologies (such as jet milling and spray drying), guided by the TPP.
• Learn strategies to prevent and overcome challenges encountered during the encapsulation of inhaled powders.